- Investing Ideas
- /
- German Biotech Breakthroughs
German Biotech Breakthroughs
UPDATED Jun 06, 2023
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
67 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 7UMUltimovacs | kr9.72 | -1.5% | 31.7% | kr4.0b | kr13.76 | PB9.4x | E61.7% | n/a | ||
| P0FEgetis Therapeutics | kr0.37 | 0% | -30.5% | kr853.0m | kr1.53 | PS20.5x | E81.1% | n/a | ||
| AB3ASarepta Therapeutics | US$117.05 | -1.3% | 81.5% | US$11.8b | US$161.74 | PS12.3x | E61.6% | n/a | ||
| 41ONOutlook Therapeutics | US$1.62 | 19.1% | 5.4% | US$449.2m | US$6.08 | PB43.8x | E64.4% | n/a | ||
| 41ONOutlook Therapeutics | US$1.45 | n/a | 37.4% | US$449.2m | US$5.44 | PB43.8x | E64.4% | n/a | ||
| YP1AImmutep | AU$1.88 | 0% | -21.7% | AU$362.1m | AU$7.68 | PS81.6x | E56.9% | n/a | ||
| DR6ACADIA Pharmaceuticals | US$22.20 | -3.5% | 41.6% | US$3.9b | US$21.15 | PS7.5x | E66.5% | n/a | ||
| 1KPAProtara Therapeutics | US$2.72 | 0% | -15.0% | US$33.4m | US$32.21 | PB0.3x | E65.3% | n/a | ||
| 2CXChemoCentryx | US$51.89 | -0.9% | 79.0% | US$3.7b | US$51.90 | PS100.3x | E69.1% | n/a | ||
| NB11Vaxart | US$3.81 | 0% | -36.9% | US$541.2m | US$10.15 | PS1150.5x | E76.0% | n/a | ||
| XUPGenfit | €4.18 | 0% | n/a | €188.3m | €10.36 | PS7.2x | E66.7% | n/a | ||
| 4KBKrystal Biotech | US$112.00 | 0.9% | 96.5% | US$3.4b | US$121.23 | PB7.1x | E67.3% | n/a | ||
| 78DAlzinova | kr0.20 | -14.4% | 13.1% | kr116.7m | n/a | PS8.1x | E155.9% | n/a | ||
| 8JDValbiotis | €4.92 | 5.8% | -22.4% | €61.9m | €11.77 | PS78.9x | E93.1% | n/a | ||
| 4RYAkeso | HK$4.10 | 0% | 99.0% | HK$28.8b | HK$6.58 | PS31.3x | E29.4% | n/a | ||
| 7V3Cantargia | kr0.43 | 15.4% | -72.9% | kr775.8m | kr1.57 | PB2.5x | E1.2% | n/a | ||
| 24HHansa Biopharma | kr3.78 | -8.6% | -30.4% | kr2.4b | kr14.15 | PS15.9x | E56.9% | n/a | ||
| P0FEgetis Therapeutics | kr0.49 | 11.0% | 42.1% | kr1.3b | kr1.33 | PS59.4x | E74.5% | n/a | ||
| 31ATheraVet | €1.85 | -1.3% | -58.6% | €6.0m | €12.30 | PS3.8x | E32.3% | n/a | ||
| O2TIVERIC bio | US$35.80 | 1.7% | 280.0% | US$5.3b | US$36.81 | PB11.3x | E61.6% | n/a | ||
| IF0InflaRx | US$3.87 | 0.9% | 187.6% | US$247.9m | US$8.77 | PB3x | E59.2% | n/a | ||
| 1AEAargenx | €370.00 | 1.6% | 20.1% | €21.0b | €451.89 | PS35.1x | E64.9% | n/a | ||
| 22ZZealand Pharma | kr.33.68 | -3.8% | 180.0% | kr.15.0b | kr.38.80 | PS140.2x | E42.1% | n/a | ||
| 6IBInnovent Biologics | HK$4.28 | -0.9% | 48.6% | HK$56.1b | HK$5.93 | PS11.2x | E56.9% | n/a |